An Italian cost-utility analysis of 20-valent pneumococcal conjugate vaccine for routine vaccination in infants
The introduction of PCV20 as a vaccination strategy for children in Italy represents a cost-effective and clinically advantageous option. Its implementation can reduce the burden of pneumococcal disease and associated healthcare costs, improving public health outcomes and the economic efficiency of the healthcare system.
Authors
- Debora Antonini (ORCID: https://orcid.org/0009-0008-9294-1241)
- Michele Basile (ORCID: https://orcid.org/0000-0002-1098-2648)
- Roberto Di Virgilio
- Eugenio Di Brino (ORCID: https://orcid.org/0000-0001-7964-3348)
- Filippo Rumi (ORCID: https://orcid.org/0000-0003-0094-0302)
- Agostino Fortunato (ORCID: https://orcid.org/0009-0004-8199-068X)
- Giuseppe Novelli (ORCID: https://orcid.org/0000-0002-7781-602X)
- Alessandra Pagliaro
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (Italy) (IT)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1080/13696998.2025.2495461
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.35